pipette
ESEspañol

Investigating AI's potential in risk-stratifying lung cancer screenings for extending screening intervals and reducing workload: A retrospective analysis of a tertiary hospital cohort

A. Nowroozi, M. Bondarenko, S. S. Brar, B. Haas, J. Brown, A. Rustagi, B. Graham, M. Hudson, G. Su, A. Yala, J. H. Sohn

PreprintBold claims, read criticallyReal-world use

In the authors' words

Objective: We aimed to 1) evaluate whether AI algorithms could identify a very low-risk sub-population Lung-RADS 1/2 cases suitable for a safe switch to biennial screening, and 2) externally validate Sybil, an imaging-based deep learning lung cancer risk prediction tool. Materials and methods: We gathered all lung cancer screenings (LCSs) from a tertiary safety-net hospital (n=3120, up to September 2024), manually extracted relevant clinical data, and analyzed Sybil's performance across various subgroups, with a specific focus on Lung-RADS 1 and 2 cases. We simulated LCS interval extension using Sybil and the Brock model risk scores calibrated on a subset of the National Lung Screening Trial (NLST). Confidence intervals were obtained through bootstrapping. Results: The median follow-up was 2.3 years (interquartile range 1.5-3.1), with a total 6-year cancer incidence rate of 2.3% (72/3120). Lung-RADS 1 and 2 cases comprised 90.5% of our scans. Sybil's overall area under the curve (AUC) ranged from 0.819 to 0.912; while its 2-year AUC for Lung-RADS 1 and 2 cases was 0.746. In the screening interval extension simulation, calibrating for a 30% shift to biennial screening translated into 33.8% of negative screens in our data being safely extended using Sybil, with no delayed cancers. The Brock model demonstrated an AUC of 0.513 on our data, with a sensitivity of 18.2% using the 1.5% threshold. Conclusion: Sybil has the potential to safely extend LCS intervals for low-risk individuals, reducing radiology workload and opening spots for life-saving new screenings.

Main resultThe abstract does not state a limitation.

Appeared: Thursday, November 5. medRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.11.03.26367146